A number of firms have modified their ratings and price targets on shares of Innoviva (NASDAQ: INVA) recently:

  • 7/31/2017 – Innoviva was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “strong-buy” rating. They now have a $16.00 price target on the stock. According to Zacks, “Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company’s portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. “
  • 7/28/2017 – Innoviva was given a new $16.00 price target on by analysts at Cowen and Company. They now have a “buy” rating on the stock.
  • 7/28/2017 – Innoviva had its “hold” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $15.00 price target on the stock.
  • 7/27/2017 – Innoviva had its “neutral” rating reaffirmed by analysts at Robert W. Baird. They now have a $13.00 price target on the stock, up previously from $11.00.
  • 7/17/2017 – Innoviva was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company’s portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. “
  • 7/3/2017 – Innoviva was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company’s portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. “

Shares of Innoviva, Inc. (NASDAQ:INVA) traded down 1.94% during midday trading on Tuesday, hitting $12.64. The company had a trading volume of 1,149,681 shares. Innoviva, Inc. has a one year low of $8.67 and a one year high of $14.55. The company’s 50 day moving average is $12.91 and its 200 day moving average is $12.36. The firm has a market cap of $1.36 billion, a price-to-earnings ratio of 15.82 and a beta of 2.56.

Innoviva (NASDAQ:INVA) last announced its quarterly earnings results on Wednesday, July 26th. The biotechnology company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of $0.28 by $0.02. Innoviva had a negative return on equity of 27.37% and a net margin of 52.56%. The company had revenue of $58.60 million during the quarter, compared to analysts’ expectations of $50.53 million. During the same quarter in the previous year, the firm earned $0.13 earnings per share. The business’s quarterly revenue was up 80.3% compared to the same quarter last year. Equities analysts forecast that Innoviva, Inc. will post $1.14 earnings per share for the current fiscal year.

In other Innoviva news, VP Theodore J. Jr. Witek sold 7,815 shares of the business’s stock in a transaction dated Monday, May 22nd. The stock was sold at an average price of $12.01, for a total value of $93,858.15. Following the completion of the sale, the vice president now owns 251,968 shares of the company’s stock, valued at $3,026,135.68. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 1.60% of the stock is owned by insiders.

Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).

Receive News & Ratings for Innoviva Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva Inc and related companies with MarketBeat.com's FREE daily email newsletter.